Tremelimumab

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.

The treatment landscape for relapsed and refractory small cell lung cancer is an area ripe for investigation.

A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA approved durvalumab in combination with standard chemotherapy as first-line treatment of adults with extensive-stage small cell lung cancer.

The addition of durvalumab to a choice of standard-of-care first-line chemotherapies conferred a sustained OS benefit for patients with extensive-stage small cell lung cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.

A randomized phase 3 trial designed to evaluate two experimental first-line treatment approaches for patients with advanced bladder cancer failed to meet its primary endpoints.

The FDA granted orphan drug designation to durvalumab and tremelimumab for treatment of patients with advanced hepatocellular carcinoma.